{
    "clinical_study": {
        "@rank": "141219", 
        "acronym": "KF_2013", 
        "arm_group": [
            {
                "arm_group_label": "Vetal Laban active", 
                "arm_group_type": "Active Comparator", 
                "description": "Vetal Laban with L. acidophilus"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vetal Laban -like product without L. acidophilus"
            }
        ], 
        "brief_summary": {
            "textblock": "A two month intervention trial assessing the effect of Vetal Laban containing L. acidophilus\n      on enhancing functional bowel wellbeing among subjects with irritable bowel syndrome (IBS)."
        }, 
        "brief_title": "Vetal Laban Intervention Trial Assessing Bowel Symptoms", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females aged 18 to 65 years\n\n          -  Subjects fulfilling Rome III criteria for IBS\n\n          -  Sufficient health and orientation for participating in the trial\n\n          -  Obtained his/her informed consent after verbal and written information.\n\n          -  Have a high probability for compliance with and completion of the study.\n\n          -  Body Mass Index (BMI) between 19 and 35.\n\n        Exclusion Criteria:\n\n          -  Diagnosed or suspected organic gastrointestinal disease (i.e. colitis, Crohn's\n             disease, celiac disease, major bowel surgery, recurrent diverticulitis) or severely\n             impaired general health including cancer and cancer therapy.\n\n          -  Lactose intolerance\n\n          -  Unwillingness to refrain from probiotic use during the trial\n\n          -  Use of antibiotics within the 3 preceding months prior to recruitment\n\n          -  Pregnant, planning pregnancy or lactating\n\n          -  Expected major lifestyle changes related to nutrition, exercise, travelling etc.\n\n          -  Participation in a clinical trial with an investigational product or drug within 3\n             months prior to screening.\n\n          -  Substance abuse\n\n          -  Subjects unable to read and understand the questionnaires"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887483", 
            "org_study_id": "KF_2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vetal Laban active", 
                "description": "Dairy product with probiotic", 
                "intervention_name": "Vetal Laban active", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Vetal Laban, Lactobacillus acidophilus"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Dairy product without probiotic", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Vetal Laban-like product without L. acidophilus"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "IBS", 
            "bowel function", 
            "probiotic"
        ], 
        "lastchanged_date": "October 21, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 Month Consumption of Vetal Laban Including L. Acidophilus on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for IBS", 
        "overall_contact": {
            "email": "research@clinart.net", 
            "last_name": "Shada Sayegh, MHSc, CCRA", 
            "phone": "443 70 55 1", 
            "phone_ext": "971(0)"
        }, 
        "overall_official": [
            {
                "affiliation": "King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia", 
                "last_name": "ABED AL LEHIBI, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "King Abdul Aziz Medical City for National Guard - Riyadh K.S.A.", 
                "last_name": "Abdullah Aljahdaly, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Danisco Sweeteners Ltd.", 
                "last_name": "Arthur C Ouwehand, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Danisco Sweeteners Ltd.", 
                "last_name": "Anna H Lyra, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Almarai Company, Saudi Arabia", 
                "last_name": "Suzanne Alodaib, MSc", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Saudi Arabia: Saudi Food & Drug Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Validated questionnaire", 
            "measure": "change in functional bowel symptoms", 
            "safety_issue": "No", 
            "time_frame": "week 0, 4, 8, 12 and 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Weekly question", 
                "measure": "change in adequate relief of bowel symptoms", 
                "safety_issue": "No", 
                "time_frame": "weekly from week 4 to week 12"
            }, 
            {
                "description": "Validated scale", 
                "measure": "change in stool defecation frequency", 
                "safety_issue": "No", 
                "time_frame": "week 0, 4, 8, 12 and 16"
            }, 
            {
                "description": "molecular analyses", 
                "measure": "change in stool microbiota", 
                "safety_issue": "No", 
                "time_frame": "week 4, 8, 12 and 16"
            }, 
            {
                "description": "Recording of adverse and serious adverse events", 
                "measure": "change in prevalence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "continuous from week 0 to 16"
            }, 
            {
                "description": "Validated scale", 
                "measure": "change in stool consistency", 
                "safety_issue": "No", 
                "time_frame": "week 0, 4, 8, 12 and 16"
            }
        ], 
        "source": "Danisco", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Almarai", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Clinart", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Danisco", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}